We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock

Delisted

ONCT was delisted on the 2nd of December, 2024.

35 hedge funds and large institutions have $9.68M invested in Oncternal Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less capital invested

Capital invested by funds: $10.6M → $9.68M (-$964K)

13% less funds holding

Funds holding: 4035 (-5)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

50% less call options, than puts

Call options by funds: $12K | Put options by funds: $24K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.93%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
5
Reduced
8
Closed
5
Calls
$12K
Puts
$24K
Net Calls
-$12K
Net Calls Change
+$17K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$7.51M
BIT
2
BlackRock Institutional Trust
California
$1.03M +$9.94K +10 +0.9%
Vanguard Group
3
Vanguard Group
Pennsylvania
$533K +$7.95K +8 +1%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$121K
BFA
5
BlackRock Fund Advisors
California
$52K -$2.98K -3 -5%
Northern Trust
6
Northern Trust
Illinois
$50K -$994 -1 -2%
BCM
7
Bridgeway Capital Management
Texas
$42K
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$41K
VKH
9
Virtu KCG Holdings
New York
$26K -$39.8K -40 -60%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$24K
Goldman Sachs
11
Goldman Sachs
New York
$23K -$6.96K -7 -23%
Tudor Investment Corp
12
Tudor Investment Corp
Connecticut
$23K
Morgan Stanley
13
Morgan Stanley
New York
$22K -$38.8K -39 -63%
Citadel Advisors
14
Citadel Advisors
Florida
$19K +$8.95K +9 +82%
Group One Trading
15
Group One Trading
Illinois
$17K -$1.99K -2 -10%
UBS Group
16
UBS Group
Switzerland
$17K +$7.95K +8 +80%
State Street
17
State Street
Massachusetts
$14K -$1.99K -2 -12%
JPTCCM
18
J.P. Turner & Co Capital Management
Georgia
$14K
BA
19
BlackRock Advisors
Delaware
$12K
DAM
20
Delta Asset Management
Tennessee
$12K
Charles Schwab
21
Charles Schwab
California
$11K
HCMT
22
Highland Capital Management (Tennessee)
Tennessee
$11K
LPL Financial
23
LPL Financial
California
$9K
Bank of America
24
Bank of America
North Carolina
$9K +$6.96K +7 +350%
OC
25
Oppenheimer & Co
New York
$7K

ONCT Hedge Fund Activity: Q1 2015 in Review

35 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2015, worth a combined $9.68M — down 9.1% from $10.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ONCT and 0 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $9.94K. The largest seller was Virtu KCG Holdings, cutting an estimated $39.8K.

  • 35 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2015, down from 40 in Q4 2014.
  • Funds reported $9.68M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2015, down 9.1% quarter-over-quarter.
  • 0 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2015 and 5 closed out, a net change of -5 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2015 was BlackRock Institutional Trust, an estimated $9.94K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2015 was Virtu KCG Holdings, an estimated $39.8K sold.

Based on aggregated 13F filings for Q1 2015.